Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Dose-escalating Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors

NCT05650385 is registered in ClinicalTrials.gov with Tasly Biopharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT05650385
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05650385 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Dose-escalating Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
Lead sponsor
Tasly Biopharmaceuticals Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
December 31, 2022
Completion date
October 31, 2025
Enrollment
68 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms malignant